Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer

Abstract

PURPOSE Liquid biopsy–based biomarkers, including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are increasingly important for the characterization of metastatic breast cancer (MBC). The aim of the study was to explore CTCs and ctDNA dynamics to better understand their potentially complementary role in describing MBC. METHODS The study retrospectively analyzed 107 patients with MBC characterized with paired CTCs and ctDNA assessments and a second prospective cohort, which enrolled 48 patients with MBC. CTCs were immunomagnetically isolated and ctDNA was quantified and then characterized through next-generation sequencing in the retrospective cohort and droplet digital polymerase chain reaction in the prospective cohort. Matched pairs variations at baseline, at evaluation one (EV1), and at progression were tested through the Wilcoxon test. The prognostic role of ctDNA parameters was also investigated. RESULTS Mutant allele frequency (MAF) had a significant decrease between baseline and EV1 and a significant increase between EV1 and progression. Number of detected alterations steadily increased across timepoints, CTCs enumeration (nCTCs) significantly increased only between EV1 and progression. MAF dynamics across the main altered genes was then investigated. Plasma DNA yield did not vary across timepoints both in the retrospective cohort and in the prospective cohort, while the short fragments fraction showed a potential role as a prognostic biomarker. CONCLUSION nCTCs and ctDNA provide complementary information about prognosis and treatment benefit. Although nCTCs appeared to assess tumor biology rather than tumor burden, MAF may be a promising biomarker for the dynamic assessment of treatment response and resistance.

Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis

“…These biological factors may also contribute to the differences in SSNVs identified. Notably, our findings are consistent with other studies in prostate cancer and other cancers that indicate that both CTCs and ctDNA can offer real-time complementary predictive information [ 17 , 62 , 63 ]. In recent years, the liquid biopsy field has gravitated towards analyzing ctDNA alone for genomic alterations due to relative ease of collection and analysis, ability to profile all patients, and access to genomic information pooled across multiple metastatic lesions.…”

An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer

“…Because of these limitations, we were unable to examine meaningful associations between patients' clinical and molecular characteristics and response to treatment. Moreover, it must be noted that the presented approach, focused on the pharmacokinetic/pharmacogenetic profiling of the patient with the aim to reach a target C min , is based on population pharmacokinetic results and does not consider the intrinsic pharmacodynamic/pharmacogenetic patient variability (Gerratana et al, 2021(Gerratana et al, , 2021Hertz et al, 2021). Additional research on this still uninvestigated source of variability should be warranted to highlight the pharmacological ground of cases of resistance or hypersensitivity to the drug, despite adequate plasma exposure, as those reported in this case series.…”

Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer

“…Along with cells, isolated nucleic acids have also been studied for their potential role as cancer biomarkers. Several studies have evaluated circulating DNA as a predictor of treatment response, disease progression [ 94 ], shorter PFS [ 95 , 96 ], and worse patient outcomes [ 97 , 98 ]. In addition, four studies evaluated mutations and/or gene expression in ctDNA.…”